FDA Investigator Michelle A Marsh

Michelle A Marsh has inspections in 1 countries as of 14 Sep 2023. Michelle A Marsh has collaborated with a combinined 1732 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
6
Last Inspection Date:
14 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America
Co-Investigator(s):
Addam S Reynolds, Alberto A Viciedo, Amalia C Himaya, Amalia Himaya, Anita Narula, PhD, Anna Kevilag, Anna Kwilas, Barry Cherney, PhD, Bichsa T Nguyen, Bichsa T Tran, Bo Chi, PhD, Brien C Fox, Carla J Lundi, Caryn M Mcnab, Cheron M Portee, Christina V Santos, Daniel W Cline, Davinna Ligons, PhD, Dawn L Wydner, Diane Cvan Leeuwen, Doan T Nguyen, PharmD, Donna Ltartaglino Besone, Dorothy J Denes, Emest F Bizjak, Emily A Walters, Erik W Koester, Erin D Mccaffery, Frances Namuswe, PhD, Haley H Seymour, Haley Seymour, Haroon Vohra (NMI), Hasan A Irier, PhD, Helen B Ricalde, Iris C Macinnes, James R Fleckenstein, Jee Chung, PhD, Jeffrey P Raimondi, Jennifer Gogley, Jennifer M Gogley, Joel Welch, PhD, John P Mistler, John R Myung, Jose M Cayuela, Julian C Hanson, Jun Park, PhD, Justine Tomasso, Ka L Wong, Kathleen R Jones, PhD, Kelvin Cheung, Kelvin X Sanders, Kendra A Biddick, Kim Lthomas Cruse, Kimberly L Schultz, Lashanda M Long, Laura Fontan, MS, Leonard H Lavi, Linda Thai, Lucas B Leake, Marcia Britt Williams, Marcus F Yambot, Margaret M Sands, Maxyne T Lam, Melissa T Roy, Michael Serrano, Mihaly S Ligmond, Mohsen Rajabi Abhari, FDA, Nicholas A Violand, Nicholas L Hunt, Nicholas Obiri, PhD, Nicola M Fenty Stewart, Nimmy Mathews, Nina Yang, Omotunde O Osunsanmi, Peter R Lenahan, Peter S Diak, Rebecca Rodriguez, Richmond K Yip, Robert D Tollefsen, Robert Darius, Roger F Zabinski, Ronald L Koller, Ronda Lebland, Ruth A Williams, Sarah Arden, Scott R Nichols, PhD, Shirley S Wen, Sidney B Priesmeyer, Sonia R Peterson, Stanley Au, Steven Fong, MS, PhD, Taichun Qin, PhD, Terri L Dodds, Thao T Kwan, Thao Tran, Thao X Tran, Tyanna N Hadley, Unnee Ranjan, Uttaniti Limchumroon (Tom), Yumi J Hiramine, Yvonne C Wilkes

Michelle A Marsh's Documents

Publish Date Document Type Title
February, 2018 FDA 483 Braeburn Pharmaceuticals Inc. - Form 483, 2018-02-08
June, 2011 EIR CELGENE CORPORATION - EIR, 2011-06-17
July, 2010 EIR TheraCom - EIR, 2010-07-22
May, 2011 EIR Amgen, Inc - EIR, 2011-05-20
February, 2018 EIR Braeburn Pharmaceuticals Inc. - EIR, 2018-02-08

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more